about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Pain play­er Al­lay makes good on launch promis­es, lock­ing down lat­est fundrais­ing round to ad­vance lead im­plant

4 years ago
Financing

Spurred on by Or­biMed part­ner's di­ag­no­sis, Van­qua Bio takes aim at neu­rode­gen­er­a­tive dis­ease with blue-chip back­ers

4 years ago
Financing

Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

4 years ago
Financing

Bris­tol My­ers rolls out 3-year mesothe­lioma da­ta for Op­di­vo/Yer­voy in first look at ES­MO slate

4 years ago
Pharma

Apel­lis turns up mixed re­sults in close­ly watched eye dis­ease tests. Are the da­ta strong enough for ap­proval?

4 years ago
R&D

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its ...

4 years ago
Startups
Deals

A new clutch of biotech blue-chip­pers joins Ob­sid­i­an's quest to craft next-gen drugs with an 'on' switch

4 years ago
Financing
R&D

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

4 years ago
R&D

Eli Lil­ly bets on an RNA base edit­ing out­fit lever­ag­ing the body's own en­zymes to re­verse mu­ta­tions

4 years ago
Deals
Discovery

Covid-19 roundup: Gates Foun­da­tion, Ex­sci­en­tia team up on pan­dem­ic an­tivi­ral dis­cov­ery pact; No­vavax opens tri­al for ...

4 years ago
Coronavirus

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

4 years ago
Deals

Macro­Gen­ics flips over an OS dud for can­cer drug Mar­gen­za in sur­pris­ing turn­around from ear­li­er da­ta

4 years ago
R&D

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

4 years ago
Deals
Cell/Gene Tx

Cas­sa­va CEO goes on the of­fen­sive over da­ta al­le­ga­tions, shout­ing down 'short at­tack'

4 years ago
R&D

Forte Bio­sciences shares col­lapse af­ter lead bac­te­ria drug flops key eczema study

4 years ago
R&D

As­sem­bly Bio ditch­es he­pati­tis B drug on liv­er tox­i­c­i­ty con­cerns in mid-stage test

4 years ago
R&D

FDA ap­proves BeiGene's Brukin­sa in rare blood can­cer amid com­pa­ny's US ex­pan­sion plans

4 years ago
Pharma
FDA+

An FTC re­view of the Sanofi/Trans­late merg­er has a new dead­line af­ter agency calls for more time

4 years ago
Deals
Pharma

A next-gen IL-2 chal­lenger bags a megaround with RA Cap­i­tal on board to ac­cel­er­ate 'mod­u­lar' drug plat­form

4 years ago
Financing
R&D

FDA ex­tends full ap­proval for Mer­ck­'s Keytru­da in 1st-line blad­der can­cer af­ter mixed ad­comm vote

4 years ago
Pharma
FDA+

A No­var­tis castoff drug gets new life at an At­las-backed start­up look­ing to blaze a trail in obe­si­ty

4 years ago
Financing
Startups

Feng Zhang's lab de­vel­ops po­ten­tial break­through in RNA edit­ing de­liv­ery us­ing 'ul­tra­com­pact' ver­sions of Cas13

4 years ago
Discovery
Cell/Gene Tx

Big mon­ey: Flag­ship's uber-plat­form play Laronde rakes in $440M to chase pro­gram­ma­ble 'eR­NA'

4 years ago
Financing
Cell/Gene Tx

The Cas­sa­va saga con­tin­ues as test­ing part­ner de­nies prepar­ing taint­ed Alzheimer's da­ta

4 years ago
R&D
First page Previous page 45678910 Next page Last page
A service from the Financial Times